A Single-Arm, Phase II Clinical Study of Sintilimab and Bevacizumab Combined With Pemetrexed and Cisplatin for Unresectable Malignant Peritoneal Mesothelioma
Overview
- Phase
- Phase 2
- Intervention
- Sintilimab, Bevacizumab , Pemetrexed , Cisplatin
- Conditions
- Malignant Peritoneal Mesothelioma, Advanced
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Progression-Free Survival (PFS)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
Detailed Description
This single-arm study aims to enroll 28 patients with unresectable malignant peritoneal mesothelioma. Enrolled patients will undergo treatment with sintilimab (200 mg), bevacizumab (7.5 mg/kg), pemetrexed (500 mg/m\^2), and cisplatin (75 mg/m\^2) administered every three weeks. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria, and after six cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs. The primary outcome measure of the study is Progression-Free Survival (PFS), while secondary outcomes include Overall Survival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Fully understand the study and voluntarily sign the informed consent form;
- •Age ≥18 years old;
- •Pathologically (including histologically or cytologically) confirmed as peritoneal mesothelioma;
- •ECOG performance status of 0-1;
- •Expected survival of ≥3 months;
- •Function of vital organs must meet the following criteria (use of any blood products and cell growth factors is not allowed within 14 days prior to enrollment): Absolute neutrophil count ≥1.5×10\^9/L; Platelets ≥100×10\^9/L; Hemoglobin ≥90g/L; Total bilirubin \<1.5 times the upper limit of normal (ULN); ALT and AST \<2.5×ULN, GPT ≤1.5×ULN; Serum creatinine ≤1×ULN; Creatinine clearance rate \>60 ml/min (Cockcroft-Gault formula);
- •Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and agree to use appropriate contraception during the trial and for 8 weeks after the last dose of trial medication; for men, must be surgically sterilized or agree to use appropriate contraception during the trial and for 8 weeks after the last dose of trial medication;
- •Have not participated in other clinical studies within 4 weeks before enrollment and during treatment. -
Exclusion Criteria
- •Unable to adhere to the study protocol or procedures;
- •Vaccination with live vaccines within 4 weeks before enrollment or expected during the study period;
- •Other malignancies within the past 5 years, except for cured basal or squamous cell skin cancer, thyroid papillary carcinoma, or in situ cervical cancer;
- •Active autoimmune diseases or a history of autoimmune diseases within 4 weeks prior to enrollment;
- •Previous allogeneic bone marrow or organ transplantation;
- •Serious cardiovascular diseases within 6 months prior to enrollment, including unstable angina or myocardial infarction;
- •Allergy to study drugs or any of their excipients;
- •International Normalized Ratio (INR) \>1.5 or Partial Thromboplastin Time (APTT) \>1.5×ULN;
- •Electrolyte abnormalities of clinical significance as judged by the investigator;
- •Uncontrolled hypertension before enrollment, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;
Arms & Interventions
single arm
Sintilimab and Bevacizumab Combined with Pemetrexed and Cisplatin
Intervention: Sintilimab, Bevacizumab , Pemetrexed , Cisplatin
Outcomes
Primary Outcomes
Progression-Free Survival (PFS)
Time Frame: 36 months
The time from the date of first administration of this regimen to the date of first documented disease progression or death due to any cause.
Secondary Outcomes
- Overall Survival (OS)(36 months)
- Objective Response Rate (ORR)(36 months)
- Disease Control Rate (DCR)(36 months)